Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Merus NV   /   Merus NV forum geopend

Aandeel Merus NV OTC:MRUS.Q, NL0011606264

Vertraagde koers (usd) Verschil Volume
51,220   -0,010   (-0,02%) Dagrange 0,000 - 0,000 14   Gem. (3M) 467,5K

Merus NV forum geopend

Volgen
1.046 Posts
Pagina: «« 1 ... 46 47 48 49 50 ... 53 »» | Laatste | Omlaag ↓
  3. Pokerface 13 oktober 2020 05:38
    PG:
    Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

    October 12, 2020 at 5:00 PM EDT
    View PDF Version
    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the expansion of their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers.

    Under a 2019 agreement, myTomorrows has been successfully providing support to eligible patients with NRG1 gene fusion cancers to participate in Merus’ Early Access Program and to receive zenocutuzumab (Zeno, MCLA-128). Expanding the relationship, myTomorrows has agreed to raise awareness of the molecular screening offered by Merus focusing on pancreatic cancer, to identify the presence of NRG1 fusions and to increase awareness of and potential enrollment in Merus’ eNRGy clinical trial. Patients recruited into the eNRGy clinical trial have cancers that harbor the NRG1 gene fusion, a rare and powerful driver of cancer cell growth found in lung, pancreatic and other solid tumor types.

    “Our medical team engages daily with physicians and patients looking for treatment options for patients with high unmet medical need. This positions us well to bolster Merus’ screening and trial enrollment efforts,” said Michel van Harten, COO of myTomorrows. “Being able to apply our experience to help with diagnosis as well as raising awareness of Merus’ offer of free molecular profiling to eligible patients with adenocarcinoma of the pancreas, is a natural extension of our mission to give patients more treatment options.”

    myTomorrows plans to leverage its expertise and ability to engage with patients, physicians and advocacy groups to raise awareness of molecular analysis for patients with adenocarcinoma of the pancreas. To further support clinical trial options for patients with adenocarcinoma of the pancreas harboring NRG1 fusion, for those eligible, Merus is offering to cover the cost of performing a full molecular analysis of the patient’s tumor, including DNA and RNA sequencing, by an independent molecular profiling company.

    “At present there are limited treatment options for patients with pancreatic cancer, and many cancers are not screened routinely for gene mutations,” said Dr. Andrew Joe, Chief Medical Officer of Merus. “myTomorrows has been a welcome addition to our global efforts to raise awareness of molecular screening for patients with pancreatic cancer and to potentially identify and recruit patients harboring NRG1 fusions for our eNRGy trial. We look forward to continuing our work with the myTomorrows team in this broader capacity.”

    Merus is currently enrolling patients on the Phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors. Further details, including current trial sites, can be found at www.ClinicalTrials.gov and Merus’ trial website at www.nrg1.com or by calling 1-833-NRG-1234.

    About NRG1 Fusions
    The NRG1 gene encodes neuregulin (also known as heregulin), the ligand for HER3. Fusions between NRG1 and partner genes are rare, tumorigenic genomic events occurring in patients with certain cancers.

    About Patient Finding Programs
    myTomorrows is committed to making drug development serve everyone better. This is done by engaging with both patients and their physicians to gain insights into needs and outcomes within the context of the pre-approval landscape. With these established relationships myTomorrows is very well positioned to assist bio-pharma companies of all sizes in their efforts to identify, engage with and offer patients the opportunity to participate in clinical research. In parallel to online activities such as disease awareness campaigns, myTomorrows also addresses physician-related barriers to Clinical Trial participation by acting as their trusted partner in information provision and proactive assistance with eligibility assessments as well as enrollment procedures.

    About myTomorrows
    myTomorrows operates as an integrated end-to-end platform serving patients, healthcare providers, and drug developers. myTomorrows offers direct support as a single point of contact for patients with a life-threatening disease where there are limited or no standard approved therapies. These patients and their physicians are provided a personalized report detailing relevant Clinical Trials and pre-approval treatment options. myTomorrows also serves as a global partner for companies developing drugs to treat patients with unmet medical needs through program management at all phases, from patient identification for Clinical Trials to the distribution of investigational drugs around the world.

    For more information please contact: medical@mytomorrows.com

    About Merus
    Merus is a clinical-stage oncology company developing innovative full-length bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and twitter.com/MerusNV.
  8. [verwijderd] 8 januari 2021 09:14
    NRG1-fusies zijn zeldzame mutaties in veel soorten solide tumoren, waaronder niet-kleincellige longkanker en alvleesklierkanker
    UTRECHT, Nederland en CAMBRIDGE, Mass., 07 januari 2021 (GLOBE NEWSWIRE) - Merus NV (Nasdaq: MRUS), een oncologiebedrijf in de klinische fase dat innovatieve, volledige multispecifieke antilichamen (Biclonics ® en Triclonics ™) tegen kanker ontwikkelt, heeft vandaag aangekondigd dat deAmerikaanse Food and Drug Administration (FDA) heeft een Fast Track Designation toegekend aan Zenocutuzumab (Zeno) voor de behandeling van patiënten met uitgezaaide solide tumoren die NRG1-genfusies (NRG1 + kankers) herbergen die zijn gevorderd met standaardbehandeling.

    Fast Track is een door de FDA verleende aanduiding die is ontworpen om de ontwikkeling te vergemakkelijken en de beoordeling van geneesmiddelen om ernstige aandoeningen te behandelen en in een onvervulde medische behoefte te voorzien.
  10. fly like an eagle 12 januari 2021 12:28
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO GI) annual meeting being held virtually from January 15-17, 2021.

    “We are pleased that MCLA-158 treatment was well tolerated in patients and that we have reached the recommended phase 2 dose,” said Andrew Joe, MD, Chief Medical Officer of Merus. “The dose expansion phase is continuing with enrollment of patients with gastric and other non-CRC cancers.”

    E-Poster Presentation:

    Title: Phase 1 dose escalation study of MCLA-158, a first in class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC)
  16. [verwijderd] 20 januari 2021 10:28
    Na beurs -6%: Reden:
    Merus NV (NASDAQ: MRUS ) is van plan om tot $ 60 miljoen aan gewone aandelen aan te bieden en te verkopen via een onderschreven openbaar bod .
    Underwriters hebben een optie van 30 dagen om tot $ 9 miljoen extra aan aandelen te kopen.
    Het bedrijf is van plan de netto-opbrengst van dit aanbod te gebruiken om de klinische ontwikkeling van zijn productkandidaten te bevorderen, voor preklinisch onderzoek en technologische ontwikkeling, werkkapitaal en algemene bedrijfsdoeleinden.
    Na een stijging van ~ 6,0% vandaag, hebben de aandelen 6,9% verloren in de handel buiten kantooruren.
1.046 Posts
Pagina: «« 1 ... 46 47 48 49 50 ... 53 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee